Compare EL & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EL | RMD |
|---|---|---|
| Founded | 1946 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9B | 36.4B |
| IPO Year | 1995 | 1995 |
| Metric | EL | RMD |
|---|---|---|
| Price | $116.69 | $256.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 12 |
| Target Price | $101.78 | ★ $291.10 |
| AVG Volume (30 Days) | ★ 3.0M | 806.6K |
| Earning Date | 02-05-2026 | 01-29-2026 |
| Dividend Yield | ★ 1.20% | 0.94% |
| EPS Growth | N/A | ★ 29.59 |
| EPS | N/A | ★ 9.77 |
| Revenue | ★ $14,446,000,000.00 | $5,257,400,000.00 |
| Revenue This Year | $7.29 | $9.85 |
| Revenue Next Year | $3.99 | $7.34 |
| P/E Ratio | ★ N/A | $26.15 |
| Revenue Growth | N/A | ★ 9.36 |
| 52 Week Low | $48.37 | $199.92 |
| 52 Week High | $120.27 | $293.81 |
| Indicator | EL | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 62.44 | 55.34 |
| Support Level | $116.01 | $250.19 |
| Resistance Level | $120.27 | $264.09 |
| Average True Range (ATR) | 3.40 | 6.02 |
| MACD | -0.02 | 0.28 |
| Stochastic Oscillator | 78.49 | 60.50 |
Estée Lauder is a leader in the global prestige beauty market, participating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and others (5%), with top-selling brands such as Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 31% of revenue from the Americas, 37% from Europe, the Middle East and Africa (including travel retail), and 32% from Asia-Pacific. Estée Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.